Nitroglycerin-mediated S-nitrosylation of proteins: a field comes full cycle.

J. Stamler
DOI: https://doi.org/10.1161/CIRCRESAHA.108.184341
IF: 23.213
2008-09-12
Circulation Research
Abstract:See related article, pages 606–614 Nitroglycerin (glyceryl trinitrate) (GTN) has been an important part of the management of patients with angina or heart failure for over 135 years. GTN works through a combined action on the venous circulation and coronary vasculature to reduce preload and improve myocardial blood flow.1 Its attributes include a potent vasodilatory action on diseased coronary vessels as well as antiischemic effects elicited in the microcirculation.1,2 Dilation of conduit vessels by GTN is mediated in large part through nitric oxide (NO) binding to heme within, and activation of, soluble guanylate cyclase (sGC) in vascular smooth muscle, thereby leading to induction of the second messenger, cyclic GMP. The microvascular action of GTN involves additional effects on red blood cells (RBCs) to improve rheology and oxygen delivery.2 GTN is an exceptionally potent vasodilator compared to other organic nitrates (isosorbide di- or mononitrates) but loses efficacy over time. Tachyphylaxis to GTN is initially specific to GTN (mechanism-based tolerance), but is ultimately associated with diminished responsiveness to other nitro(so)vasodilators (cross-tolerance) and even other classes of drugs (as a result of fluid retention and perhaps cellular injury).1,3,4 Tolerance and cross-tolerance have generally been thought of in terms of an NO deficiency, resulting in attenuated sGC activity.5,6 Sayed et al had found recently that S -nitrosylation of sGC (the addition of an NO group to a cysteine thiol) by endothelium-derived NO inhibits sGC activity,7 and they now report that exposure to GTN can …
What problem does this paper attempt to address?